They reported that METTL14 was overexpressed in gemcitabine-resistant pancreatic cancer cells and p65 (a transcription factor) promoted the expression of METTL14 and subsequently upregulated cytidine deaminase (CDA), a gemcitabine inhibitor. Here, CDA is linked to pancreatic neoplasm.